1. women who have recently been pregnant or breast-feeding. 2. having a history of active gastrointestinal bleeding in the past 3 months. 3. blood routine examination showed that the platelet count was \< 30×109/l. 4. patients with coagulation disorders. 5. unable to understand the potential risks and benefits of the study, and unable to follow up the evaluation as required. 6. having no capacity for civil conduct. 7. a history of drug or alcohol abuse. 8. allergic to aspirin. 9. influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia, organized pneumonia, etc. 10. patients with cardiac stent placement (\< 1 year). 11. any more complex medical problems that may interfere with research behavior or lead to increased risk, such as malignant tumors, blood diseases, liver diseases, aids, viral hepatitis, etc.

1. women who have recently been pregnant or breast-feeding. 2. having a history of active gastrointestinal bleeding in the past 3 months. 3. blood routine examination showed that the platelet count was \< 30×109/l. 4. patients with coagulation disorders. 5. unable to understand the potential risks and benefits of the study, and unable to follow up the evaluation as required. 6. having no capacity for civil conduct. 7. a history of drug or alcohol abuse. 8. allergic to aspirin. 9. influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia, organized pneumonia, etc. 10. patients with cardiac stent placement (\< 1 year). 11. any more complex medical problems that may interfere with research behavior or lead to increased risk, such as malignant tumors, blood diseases, liver diseases, aids, viral hepatitis, etc.

women who have recently been pregnant or breast-feeding. having a history of active gastrointestinal bleeding in the past 3 months. blood routine examination showed that the platelet count was < 30×109/l. patients with coagulation disorders. unable to understand the potential risks and benefits of the study, and unable to follow up the evaluation as required. having no capacity for civil conduct. a history of drug or alcohol abuse. allergic to aspirin. influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia, organized pneumonia, etc. patients with cardiac stent placement (< 1 year). any more complex medical problems that may interfere with research behavior or lead to increased risk, such as malignant tumors, blood diseases, liver diseases, aids, viral hepatitis, etc.

women who have recently been pregnant or breast-feeding. having a history of active gastrointestinal bleeding in the past 3 months. blood routine examination showed that the platelet count was < 30×109/l. patients with coagulation disorders. unable to understand the potential risks and benefits of the study, and unable to follow up the evaluation as required. having no capacity for civil conduct. a history of drug or alcohol abuse. allergic to aspirin. influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia, organized pneumonia, etc. patients with cardiac stent placement (< 1 year). any more complex medical problems that may interfere with research behavior or lead to increased risk, such as malignant tumors, blood diseases, liver diseases, aids, viral hepatitis, etc.

1. women who have recently been pregnant or breast-feeding. 2. having a history of active gastrointestinal bleeding in the past 3 months. 3. blood routine examination showed that the platelet count was < 30×109/l. 4. patients with coagulation disorders. 5. unable to understand the potential risks and benefits of the study, and unable to follow up the evaluation as required. 6. having no capacity for civil conduct. 7. a history of drug or alcohol abuse. 8. allergic to aspirin. 9. influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia, organized pneumonia, etc. 10. patients with cardiac stent placement (< 1 year). 11. any more complex medical problems that may interfere with research behavior or lead to increased risk, such as malignant tumors, blood diseases, liver diseases, aids, viral hepatitis, etc.

1. women who have recently been pregnant or breast-feeding. 2. having a history of active gastrointestinal bleeding in the past 3 months. 3. blood routine examination showed that the platelet count was < 30×109/l. 4. patients with coagulation disorders. 5. unable to understand the potential risks and benefits of the study, and unable to follow up the evaluation as required. 6. having no capacity for civil conduct. 7. a history of drug or alcohol abuse. 8. allergic to aspirin. 9. influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia, organized pneumonia, etc. 10. patients with cardiac stent placement (< 1 year). 11. any more complex medical problems that may interfere with research behavior or lead to increased risk, such as malignant tumors, blood diseases, liver diseases, aids, viral hepatitis, etc.